Abstract:Aging is a common risk factor for brain and bone degenerative diseases such as Alzheimer's disease and osteoporosis. During aging, myeloid cells undergo abnormal expansion and exhibit impaired function, possibly caused by mitochondrial dysfunction and metabolic reprogramming. Myeloid cells can be the co‐regulator of the brain–bone degenerative diseases. Metformin and melatonin are promising candidates for the brain–bone degenerative diseases. Brain and bone degenerative diseases such as Alzheimer's disease and osteoporosis are common in the aging population and lack efficient pharmacotherapies. Myeloid cells are a diverse group of mononuclear cells that plays important roles in development, immune defense, and tissue homeostasis. Aging drastically alters the expansion and function of myeloid cells, which might be a common pathogenesis of the brain–bone degenerative diseases. From this perspective, the role of myeloid cells in brain–bone degenerative diseases is discussed, with a particular focus on metabolic alterations in myeloid cells. Furthermore, targeting myeloid cells through metabolic regulation via drugs such as metformin and melatonin is proposed as a potential therapy for the clinical treatment of brain–bone diseases.

Myeloid Cells As a Promising Target for Brain–Bone Degenerative Diseases from a Metabolic Point of View